Posted on

Survey Quantifies COVID-19’s Impact on Oncology

Posted on

An international survey provides new insights into how COVID-19 has affected, and may continue to affect, the field of oncology. The survey showed that “COVID-19 has had a major impact on the organization of patient care, on the well-being of caregivers, on continued medical education, and on clinical trial activities in oncology,” stated Guy Jerusalem, MD,…

Read more

Posted on

Safety a Concern for Vulvovaginal Atrophy Treatments in Breast Cancer Survivors

Posted on

For women with breast cancer and vulvovaginal atrophy (VVA) unresponsive to non-hormonal therapy, other treatments may be effective, but safety is “controversial and a major concern,” say authors of a systematic review. “I was surprised that clinical studies assessing the safety of the vaginal laser or androgen therapies, with regard to serum estradiol levels or…

Read more

Posted on

Many Advanced Countries Missing Targets for HCV Elimination

Posted on

Eleven high-income countries are on track to meet World Health Organization targets to eliminate hepatitis C infection by 2030, compared with nine countries 2 years ago, researchers report. But 28 countries, including the United States, are not expected to eliminate HCV until 2050. “In the countries making progress, the common elements are political will, a clear national…

Read more

Posted on

Gout Medication Prevents Progression of Coronary Disease

Posted on

Colchicine usage found to reduce the risk of cardiovascular death, heart attack and stroke by almost one third, according to an Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands. The trial confirmed that low dose colchicine…

Read more

Posted on

Updated Guidelines Endorse Genomic Tests, Targeted Treatments for Metastatic Pancreatic Cancer

Posted on

Patients with metastatic pancreatic cancer should undergo germline and somatic testing to identify those who can benefit from targeted therapies, according to an updated guideline from the American Society of Clinical Oncology (ASCO). The 2018 ASCO guideline focused on second-line therapy for patients who had experienced progression or intolerable toxicity after first-line therapy. The updated…

Read more

Posted on

Ensartinib Bests Crizotinib in ALK+ Non-Small Cell Lung Cancer

Posted on

Ensartinib significantly prolonged progression-free survival, compared with crizotinib, in patients with ALK-positive non-small-cell lung cancer (NSCLC) in the eXalt3 study. Ensartinib, being developed by Xcovery Holdings, is a potent, next-generation, once-daily oral ALK inhibitor with broad preclinical activity against ALK-resistance mutations. “Its potency is more than 10 times greater than that of crizotinib in enzyme…

Read more

Posted on Leave a comment

Lung Cancer Mortality Rate: New Findings

Posted on Leave a comment

In the United States in recent years, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply, due primarily to recent advances in treatment, said new study. The study was led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. “Reduced tobacco consumption…

Read more

Posted on

Aspirin may Hasten Progression of Cancers in Elderly Patients

Posted on

Aspirin may decrease the risk of developing cancer, according to the study conducted by a binational team led by researchers at Massachusetts General Hospital (MGH), the Berman Center in Minnesota, and Monash University in Australia. Compelling evidence from clinical trials that included predominantly middle-aged adults demonstrates that aspirin may reduce the risk of developing cancer,…

Read more

Posted on

Canakinumab Holds Potential In Treating Large Joint Osteoarthritis

Posted on

Patients receiving interleukin-1£] (IL-1£]) inhibitors had lower rates of total hip or total knee replacements over an average follow up of 3.7 years, according to an exploratory analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which is a randomized double-blind, placebo-controlled trial. These findings are important, as no treatments currently exist that…

Read more